A Study of ASP8302 in Participants With Underactive Bladder

NCT ID: NCT03702777

Last Updated: 2024-11-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-20
• Study Completion Date: 2020-04-28

Brief Summary

The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in participants with UAB, to investigate the pharmacokinetics of ASP8302 in participants with UAB and to support the development of the UAB - Patient Reported Outcome (PRO).

Detailed Description

The study will comprise a screening visit, followed by a treatment period and a 2-week follow-up period, in total 8 weeks. Participants will visit the clinic at screening (visit 1) and every 2 weeks (visit 2, 3, 4, and 5). During the course of the study assessments will be performed at the visits.

Conditions

Underactive Bladder

Keywords

Underactive Bladder; ASP8302

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

ASP8302 100mg

Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.

Group Type: EXPERIMENTAL

ASP8302

Intervention Type: DRUG

Oral Capsule

Placebo

Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral Capsule

Interventions

ASP8302

Oral Capsule

Intervention Type: DRUG

Placebo

Oral Capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

At visit 1:

• Subject is diagnosed with UAB, defined as a bothersome chronic incomplete bladder emptying:

• clinical condition is present for ≥ 6 months before screening, and
• subject has a PVR ≥ 75 mL (measured by ultrasound after uroflowmetry; V1-PVRUS1).
• Subject on clean intermittent catheterization (CIC) should have been on CIC for at least 1 month and should be able to void spontaneously and not be completely dependent on CIC.
• Female subject must either:

• Be of non-childbearing potential; post-menopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
• Or, if of childbearing potential; agrees not to try to become pregnant during the study and for 28 days after the final study drug administration, agrees to have a serum pregnancy test on all visits, have a negative serum pregnancy test at the screening visit, and agrees to consistently use 1 form of highly effective birth control starting at screening and throughout the study period and for 28 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 28 days after the final study drug administration.
• Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
• A sexually active male subject with female partner(s) of childbearing potential is eligible if he agrees to use a male condom starting at screening and continue throughout study treatment and for 90 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile, his female partner(s) is utilizing 1 form of highly effective birth control starting at screening and will continue throughout study treatment and for 90 days after the male subject receives the final study drug administration.
• Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
• Male subject with a pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while participating in this study.

At visit 2:

• Subject has a PVR ≥ 100 mL (measured by catheterization, i.e., PVRC2).
• Subject has a VVST ≥ 50 mL and a bladder voiding efficiency ((BVE) (V2_BVE)) ≥ 10%. The VVST and V2_PVRC2 will be used to calculate V2_BVE = [VVST/(V2_PVRC2 + VVST)] times 100.

Exclusion Criteria

At visit 1:

Related to lower urinary tract:

• Subject has significant BOO:

• Subject has clinically significant urethral stricture (e.g., requiring surgery).
• Female subject has uterus prolapse ≥ Grade 2 Shaw's system (up to or outside the introitus), moderate or severe cystocele (reaches or protrudes outside the introitus).
• Male subject has a bladder outlet obstruction index (BOOI) ≥ 40 cm H2O on pressure flow study (PFS) (either performed on screening or within 12 months of the screening visit), or -if PFS is not available-a prostate volume (PV) of > 40 mL (Europe) > 30 mL (Japan) on ultrasound (either performed on screening or within 6 months of the screening visit). Note: if PFS is available and PV is above the cut-off level, the subject is not to be excluded if bladder outlet obstruction index (BOOI) is < 40.
• Other condition that constitutes significant BOO.
• Subject is known to have urgency urinary incontinence that is clinically significant.
• Subject is known to have 1 or more bladder diverticuli that is/are clinically significant.
• Subject is known to have vesico-ureteral/renal reflux that is clinically significant.
• Subject has a urinary catheter in situ (including suprapubic catheters).
• Subject is known to have 1 of the following conditions as a primary cause for subject's UAB, or a condition that could potentially influence treatment outcome:

• Neurological lesion or condition, including cerebrovascular accident, spinal lumbar disc hernia, spinal cord injury, multiple sclerosis, Parkinson's disease, Guillain-Barré syndrome, pudendal, hypogastric or pelvic nerve lesion. Diabetes mellitus is allowed if controlled with or without medical treatment (e.g., HbA1C < 7%).
• Increased pelvic floor muscle activity during voiding (e.g., dyssynergic striated sphincteric activity/striated sphincteric activity during voiding, Fowler syndrome and pelvic floor muscle spasm).
• Previous bladder surgery (e.g., bladder augmentation or reduction surgery, latissimus dorsi detrusor myoplasty). Prior Benign Prostatic Obstruction surgery or pelvic organ prolapse surgery is allowed if performed more than 6 months prior to screening.
• Previous implant surgery for incontinence still in situ (e.g., tape, sling or artificial sphincter)
• Significant active urological pain syndrome.
• Previous pelvic radiation therapy.
• Dependence on use of a manual assistance method intended to improve bladder emptying (e.g., Credé's maneuver or suprapubic tapping).

Related to (previous or current) treatment and/or study drug:

• Subject is receiving 1 or more of the following non-medication therapies:

• Electrostimulation therapy, e.g., neurostimulation/modulation or sacral nerve stimulation in the past 3 months.
• Intravesical or injection based treatment (e.g., botulinum toxin injections in urethra or bladder in the past 12 months).
• An ongoing bladder training program and/or pelvic floor muscle exercises, which started within 6 weeks prior to visit 1.
• Muscle-derived stem cell injection in the bladder or urethra or bladder transplantation at any time prior to screening.
• Subject is using prohibited medications or subject is using restricted medications under conditions different to those specified in the concomitant medication section.
• Subject has a known or suspected hypersensitivity to ASP8302 or any of the inactive ingredients.

Related to concomitant conditions:

• Subject is known to have inflammatory bowel disease or clinically significant diarrhea.
• Subject is known to be immunocompromised due to conditions such as human immunodeficiency virus/acquired immune deficiency syndrome or hepatitis C.
• Subject has been diagnosed with clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to visit 1, such as myocardial infarction, uncontrolled angina/coronary artery disease, significant ventricular arrhythmias and heart failure (New York Heart Association class III/IV).
• Subject has been diagnosed with clinically significant asthma, chronic bronchitis and/or chronic obstructive pulmonary disease.
• Subject is known to have a mean Fridericia corrected QT interval (QTcF) > 430 ms for males or > 450 ms for females, a pre-existing long QT syndrome or hypokalemia.
• Subject has a clinically significant abnormal 12-lead ECG.
• Subject has current or previous malignant disease of the pelvis. Subjects with a history of (non-pelvic) cancer are considered eligible if the subject has undergone therapy and the subject has been considered disease free for at least 5 years. Subject with completely excised basal cell carcinoma or squamous cell carcinoma of the skin and completely excised cervical cancer in situ are also considered eligible.
• Subject is known to have moderate to severe hepatic impairment (i.e., Child-Pugh class B or C).
• Subject is known to have severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2.
• Subject is known to have current or history of alcohol and/or drug abuse within the last 24 months prior to screening.
• Subject has clinical signs and symptoms of a urinary tract infection (UTI), which is combined with a result of urine test (e.g., positive urine culture containing > 100,000 cfu/mL in midstream urine). If a UTI is confirmed in the visit 1 sample, the run-in period should be stopped. After successful treatment of the UTI, the subject can be rescreened and if eligible enroll in the study. If the subject has asymptomatic bacteriuria (i.e., a positive urine culture without clinical signs and symptoms of a UTI), the subject should not be excluded.
• Subject has any of the following abnormal liver or kidney function parameters (as assessed in visit 1 sample):

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin increased to > 1.5 times the upper limit of normal (ULN).
• Gamma glutamyltransferase (γ-GT) increased to > 3 times the ULN.
• eGFR < 45 mL/min/1.73 m^2 based on the Modification of Diet in Renal Disease formula.

General:

• Subject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
• Subject is known to have any condition, which makes the subject unsuitable for study participation.

At visit 2:

• Subject has severe overactive bladder (OAB), i.e., experienced 3 or more episodes of urgency (Patient Perception of Intensity of Urgency Scale (PPIUS) grade 3 or 4), during the 3-day micturition diary period prior to visit 2.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Astellas Pharma Europe B.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Astellas Pharma Europe B.V.

Locations

Site DE49001

Duisburg, , Germany

Site DE49002

Duisburg, , Germany

Site DE49004

Gronau, , Germany

Site DE49003

Mönchengladbach, , Germany

Site JP81009

Nagoya, Aichi-ken, Japan

Site JP81008

Ōbu, Aichi-ken, Japan

Site JP81007

Yoshida-gun, Fukui, Japan

Site JP81006

Asahikawa, Hokkaido, Japan

Site JP81005

Sapporo, Hokkaido, Japan

Site JP81015

Sapporo, Hokkaido, Japan

Site JP81002

Kobe, Hyōgo, Japan

Site JP81012

Kurashiki, Okayama-ken, Japan

Site JP81011

Sayama, Osaka, Japan

Site JP81001

Shimotsuga-gun, Tochigi, Japan

Site JP81003

Fukuoka, , Japan

Site JP81004

Kumamoto, , Japan

Site JP81010

Saga, , Japan

Site JP81013

Shizuoka, , Japan

Site NL31003

Eindhoven, , Netherlands

Site NL31002

Maastricht, , Netherlands

Site NL31001

Rotterdam, , Netherlands

Site PL48004

Mysłowice, , Poland

Site PL48003

Piaseczno, , Poland

Site PL48002

Szczecin, , Poland

Site PL48001

Warsaw, , Poland

Site SK42103

Košice, , Slovakia

Site SK42101

Nitra, , Slovakia

Site SK42102

Trenčín, , Slovakia

Site UK44002

Bristol, , United Kingdom

Countries

Germany; Japan; Netherlands; Poland; Slovakia; United Kingdom

References

van Till JWO, Arita E, Kuroishi K, Croy R, Oelke M, van Koeveringe GA, Chapple CR, Yamaguchi O, Abrams P. Muscarinic-3-receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial. Neurourol Urodyn. 2022 Jun;41(5):1139-1148. doi: 10.1002/nau.24931. Epub 2022 Apr 14.

Reference Type: DERIVED

PMID: 35419807 (View on PubMed)

Related Links

https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=400

Link to results on the Astellas Clinical Study Results Website.

Other Identifiers

2017-003693-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

8302-CL-0201

Identifier Type: -

Identifier Source: org_study_id